BIOMAT Database Logo BIOMAT Database Logo

Use of zidovudine for drug misusers infected with human immunodeficiency virus. 1989

F M Cowan, and G Jones, and J Bingham, and P J Flegg, and L R MacCallum, and J Whitelaw, and D Hargreave, and J A Gray, and P D Welsby, and R P Brettle
Department of Infectious Diseases, City Hospital, Edinburgh, U.K.

The use of zidovudine in drug misusers, especially current drug misusers, has not been extensively studied. Since periods of abstinence may be interspersed with drug misuse, it is necessary to establish the safety of zidovudine in injection drug misuse-related human immunodeficiency virus (HIV) infection under a variety of conditions. HIV serology became available in October 1985 and we have now examined medically 289 HIV seropositive patients, 85% of whom acquired their infection via injection drug misuse. Since March 1987 we have treated 40 individuals with zidovudine, 25 of whom were former or current injection drug misusers and one who was a heterosexual contact of a drug misuser. Eighteen patients were taking various types of opiates. Six of this latter group injected either occasionally or regularly whilst taking zidovudine. There were no adverse clinical events associated with zidovudine treatment and continued opiate drug misuse whether by mouth or by injection. Although defaults from clinic visits were a problem, these defaults were not associated with any particular form of drug misuse. Compliance with zidovudine therapy as judged by change in the mean corpuscular volume was no different for the various risk groups. In our experience it is possible to treat safely current and former drug misusers with zidovudine.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009294 Narcotics Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. Analgesics, Narcotic,Narcotic Analgesics,Narcotic,Narcotic Effect,Narcotic Effects,Effect, Narcotic,Effects, Narcotic
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency

Related Publications

F M Cowan, and G Jones, and J Bingham, and P J Flegg, and L R MacCallum, and J Whitelaw, and D Hargreave, and J A Gray, and P D Welsby, and R P Brettle
Use of didanosine in zidovudine-intolerant patients infected with human immunodeficiency virus.
February 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
F M Cowan, and G Jones, and J Bingham, and P J Flegg, and L R MacCallum, and J Whitelaw, and D Hargreave, and J A Gray, and P D Welsby, and R P Brettle
Prescription drug use patterns of human immunodeficiency virus-infected patients taking zidovudine. Walter Reed Retrovirus Research Group.
September 1989, DICP : the annals of pharmacotherapy,
F M Cowan, and G Jones, and J Bingham, and P J Flegg, and L R MacCallum, and J Whitelaw, and D Hargreave, and J A Gray, and P D Welsby, and R P Brettle
Zidovudine therapy in thrombocytopenic human immunodeficiency virus-infected children.
November 1991, The Pediatric infectious disease journal,
F M Cowan, and G Jones, and J Bingham, and P J Flegg, and L R MacCallum, and J Whitelaw, and D Hargreave, and J A Gray, and P D Welsby, and R P Brettle
Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus.
August 1992, Therapeutic drug monitoring,
F M Cowan, and G Jones, and J Bingham, and P J Flegg, and L R MacCallum, and J Whitelaw, and D Hargreave, and J A Gray, and P D Welsby, and R P Brettle
Use of zidovudine in human immunodeficiency virus-induced hepatitis.
May 1994, Clinical and diagnostic laboratory immunology,
F M Cowan, and G Jones, and J Bingham, and P J Flegg, and L R MacCallum, and J Whitelaw, and D Hargreave, and J A Gray, and P D Welsby, and R P Brettle
Development and significance of zidovudine resistance in children infected with human immunodeficiency virus.
July 1993, The Journal of pediatrics,
F M Cowan, and G Jones, and J Bingham, and P J Flegg, and L R MacCallum, and J Whitelaw, and D Hargreave, and J A Gray, and P D Welsby, and R P Brettle
Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus.
May 1994, The Journal of infectious diseases,
F M Cowan, and G Jones, and J Bingham, and P J Flegg, and L R MacCallum, and J Whitelaw, and D Hargreave, and J A Gray, and P D Welsby, and R P Brettle
Pharmacokinetic interaction of megestrol acetate with zidovudine in human immunodeficiency virus-infected patients.
November 1997, Antimicrobial agents and chemotherapy,
F M Cowan, and G Jones, and J Bingham, and P J Flegg, and L R MacCallum, and J Whitelaw, and D Hargreave, and J A Gray, and P D Welsby, and R P Brettle
Human immunodeficiency virus in drug misusers and increased consultation in general practice.
September 1989, The Journal of the Royal College of General Practitioners,
F M Cowan, and G Jones, and J Bingham, and P J Flegg, and L R MacCallum, and J Whitelaw, and D Hargreave, and J A Gray, and P D Welsby, and R P Brettle
A pro-drug of zidovudine with enhanced efficacy against human immunodeficiency virus.
April 1989, Biochemical and biophysical research communications,
Copied contents to your clipboard!